



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUNE 30, 2020

PTAS

JANET TSE
C/O GENENTECH, INC.
1 DNA WAY, M.S. 49
SOUTH SAN FRANCISCO, CA 94080

506128069

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/26/2020

REEL/FRAME: 053067/0225
NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: P35574-WO AND P35574-US

ASSIGNOR:
PHARMARON, INC.

DOC DATE: 06/04/2020

ASSIGNEE:
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 63035381

FILING DATE: 06/05/2020

PATENT NUMBER:

ISSUE DATE:

TITLE: PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES
THEREOF

APPLICATION NUMBER:
PATENT NUMBER:
PCT NUMBER: CN2019091712
TITLE:

FILING DATE:
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PHARMARON BEIJING CO., LTD.	06/04/2020
RECEIVING PARTY DATA	
Name:	PHARMARON, INC.
Street Address:	201 EAST JEFFERSON STREET
City:	LOUISVILLE
State/Country:	KENTUCKY
Postal Code:	40202
PROPERTY NUMBERS Total: 2	
Property Type	Number
PCT Number:	CN2019091712
Application Number:	63035381
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
Phone:	6502252906
Email:	jet@gene.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	JANET TSE
Address Line 1:	1 DNA WAY
Address Line 2:	MAIL STOP 49
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P35574-WO AND P35574-US
NAME OF SUBMITTER:	JANET TSE
Signature:	/Janet Tse/
Date:	06/26/2020

Total Attachments: 1

source=P35574 Pharmaron Beijing to Pharmaron signed assignment#page1.tif

RECEIPT INFORMATION

EPAS ID: PAT6174773

Receipt Date: 06/26/2020

ASSIGNMENT

This assignment is by PHARMARON, INC., a corporation with a mailing address of 201 East Jefferson Street, Louisville, Kentucky 40202, United States of America, (referred to in this Assignment as "ASSIGNOR"), has full right, title and interest in and to a new and useful invention in

PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF

for which an International Patent Application No. PCT/CN2019/091712 (Docket No. **P35574-WO**) has been filed on **18 June 2019**; and U.S. Provisional Patent Application No. 63/035381¹ (Docket No. **P35574-US**) has been filed on 5 June 2020¹

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the undersigned ASSIGNOR has and does hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all applications filed and Letters Patents granted and issued therefor, or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

The undersigned ASSIGNOR covenants and agrees to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by the undersigned ASSIGNOR includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance, all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by the undersigned ASSIGNOR in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon the undersigned ASSIGNOR, its respective heirs, legal representatives and assigns.

The undersigned ASSIGNOR hereby warrants and represents that it has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF I/we undersign as follows;

For and on behalf of **PHARMARON, INC.**

Date: 6/4/2020

By: JANE J. ZHANG
Name: JANE J. ZHANG
Title: C.R.O.

¹Assignor and Assignee hereby authorize Genentech, Inc., and their representatives and assigns to insert the application number and filing date information when they become known.